Medicare would have saved 18% to 30% on newly launched drugs from 2015 to 2019 if it had used domestic reference pricing to control prices, and domestic reference prices for most drugs were even above the prices suggested by the Institute for Clinical and Economic Review, according to a report by West Health Policy Center, the University of Pittsburg and the University of California, San Diego. House Democrats’ H.R. 3 would base Medicare negotiation on international drug prices, but lobbyists...